ALK and non-small cell lung carcinoma: A small portion of non-small-cell lung cancers (NSCLC) involve activating rearrangements of the ALK gene, the most common of which is the EML4-ALK fusion gene (2 to 7% of all NSCLC), the target of ALK inhibitors [45].